Breaking News Instant updates and real-time market news.

CHMA

Chiasma

$4.90

0.03 (0.62%)

07:24
01/10/20
01/10
07:24
01/10/20
07:24

Chiasma CEO says 2019 was a 'successful year'

Chiasma reviewed its 2019 highlights and previewed its anticipated 2020 corporate milestones. On December 26, Chiasma resubmitted its NDA to the U.S. Food and Drug Administration for its investigational octreotide capsules product candidate, MYCAPSSA, for the maintenance treatment of adults with acromegaly. The positive results from the CHIASMA OPTIMAL trial, which was conducted under a Special Protocol Assessment agreement with the FDA, support the NDA resubmission. Chiasma expects a six-month review of the NDA resubmission. The NDA resubmission marks an important milestone in the company's effort to bring an oral somatostatin analog to patients. Following anticipated NDA approval, and in order to have commercial supply of MYCAPSSA product for launch, Chiasma expects to submit two manufacturing supplements to provide for an additional active pharmaceutical ingredient manufacturer and an additional commercial-scale manufacturing site affiliated with the API manufacturer currently referenced in the NDA. Chiasma is currently procuring API from both sources in anticipation of NDA approval. Chiasma expects to have adequate product available to support its planned commercial launch in the fourth quarter of 2020, subject to FDA's timely approval of the NDA and either of the manufacturing supplements. In July, Chiasma announced that the primary endpoint of the CHIASMA OPTIMAL trial, the proportion of patients biochemically controlled at the end of the trial, was achieved. Additionally, all four secondary endpoints were met. The CHIASMA OPTIMAL trial was conducted under an SPA agreement with the FDA and evaluated MYCAPSSA for the maintenance treatment of adults with acromegaly. Three Posters Presented at ENDO 2019 Highlighted Significant Unmet Needs in U.S. Acromegaly Patients: Data presented concluded that patients currently treated on injectable somatostatin analog therapies experience a significant disease burden and treatment dissatisfaction even when biochemically-controlled using existing therapies. The MPOWERED trial, designed to support approval of MYCAPSSA in the European Union for acromegaly, completed enrollment in June 2019. As of January 2020, the randomization was completed. Responders to the octreotide capsules were randomized per the protocol into the nine-month randomized controlled phase. Chiasma began its transformation into a commercial-ready organization with the appointment of a commercially-experienced chief executive officer and the addition of experienced leaders in marketing, market access and patient services. Chiasma has also expanded its medical affairs function, including hiring a leader with strategic medical and scientific expertise. "2019 was a successful year for Chiasma, highlighted by the positive results from the Phase 3 CHIASMA OPTIMAL trial and the NDA resubmission," said CEO Raj Kannan. "Looking ahead, 2020 has the potential to be a transformational year for our company as we focus on executing a successful launch of the first oral somatostatin analog for the treatment of acromegaly."

CHMA Chiasma
$4.90

0.03 (0.62%)

06/06/19
CANT
06/06/19
NO CHANGE
Target $18
CANT
Overweight
New CEO a 'significant positive' for Chiasma, says Cantor Fitzgerald
Cantor Fitzgerald analyst Brandon Folk believes the appointment of Raj Kannan as CEO is a "significant positive" for Chiasma. Kannan brings significant commercial experience to the company, and the fact that it was able to retain Mark Fitzpatrick as President is a further positive, Folk tells investors in a research note. The analyst views the news as another positive step toward a potential Mycapssa launch and the commercial readiness of Chiasma. He keeps an Overweight rating on the stock with an $18 price target.
07/10/19
CANT
07/10/19
NO CHANGE
Target $18
CANT
Overweight
Chiasma called a top idea for second half of 2019 at Cantor Fitzgerald
After meeting with management, Cantor Fitzgerald analyst Brandon Folkes calls Chiasma a top idea for the second half of 2019. The analyst reiterates an Overweight rating on the shares with an $18 price target. Based on the totality of evidence from CH-ACM-01 and the MPOWERED six-month run-in phase, there is a high likelihood of OPTIMAL reporting responder rates in the 50-%60% range, Folkes tells investors in a research note. However, the bar for a successful trial readout is "meaningfully lower" in the ~30% range, provided the result is statistically significant, adds the analyst. He expects data readouts, approvals, and upward earnings revisions to drive Chiasma shares higher.
07/31/19
PIPR
07/31/19
INITIATION
Target $11
PIPR
Overweight
Chiasma initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff started Chiasma with an Overweight rating and $11 price target. The company is developing Mycapssa, the first oral therapy for acromegaly, Tenthoff tells investors in a research note. He projects global Mycapssa sales of $501M in 2028 and sees approval in mid-2020 with a U.S. launch in 2021.
07/31/19
07/31/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Verra Mobility (VRRM) initiated with a Neutral at Goldman Sachs. 2. Myomo (MYO) initiated with a Buy at Ascendiant. 3. Chiasma (CHMA) initiated with an Overweight at Piper Jaffray. 4. IAA (IAA) initiated with a Buy at Jefferies. 5. Veracyte (VCYT) initiated with a Buy at Lake Street. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

IBCP

Independent Bank

$22.51

-0.26 (-1.14%)

16:19
01/20/20
01/20
16:19
01/20/20
16:19
Hot Stocks
Independent Bank announces 11% increase in quarterly cash dividend »

Independent Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 18

    Feb

  • 19

    Feb

JAZZ

Jazz Pharmaceuticals

$151.00

-0.56 (-0.37%)

16:17
01/20/20
01/20
16:17
01/20/20
16:17
Hot Stocks
Jazz Pharmaceuticals receives EU Marketing Authorization for Sunosi »

Jazz Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

AMRN

Amarin

$19.91

-0.15 (-0.75%)

16:13
01/20/20
01/20
16:13
01/20/20
16:13
Recommendations
Amarin analyst commentary  »

Amarin remains in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

, SPX

S&P 500

$0.00

(0.00%)

16:09
01/20/20
01/20
16:09
01/20/20
16:09
Periodicals
Macron, Trump declare truce in digital tax dispute, Reuters reports »

French President Emmanuel…

SPY

SPDR S&P 500 ETF Trust

$331.98

1.08 (0.33%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

XOM

Exxon Mobil

$68.55

-0.26 (-0.38%)

, HES

Hess Corp.

$69.87

-0.45 (-0.64%)

16:07
01/20/20
01/20
16:07
01/20/20
16:07
Periodicals
Guyana's first oil cargo to be refined by Exxon in the U.S., Reuters reports »

A vessel carrying…

XOM

Exxon Mobil

$68.55

-0.26 (-0.38%)

HES

Hess Corp.

$69.87

-0.45 (-0.64%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 31

    Jan

  • 23

    Mar

TSLA

Tesla

$510.34

-3.065 (-0.60%)

16:04
01/20/20
01/20
16:04
01/20/20
16:04
Periodicals
Tesla rebuffs U.S. safety recall petition, Reuters reports »

Tesla said there was no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 24

    Feb

  • 23

    Mar

  • 23

    Mar

EADSY

Airbus

$0.00

(0.00%)

16:02
01/20/20
01/20
16:02
01/20/20
16:02
Periodicals
Airbus unit to offer product to help airlines with revenue risk, Reuters says »

A subsidiary of Airbus is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAPL

Apple

$318.66

3.33 (1.06%)

15:41
01/20/20
01/20
15:41
01/20/20
15:41
Periodicals
Apple CEO says global corporate tax system must be overhauled, Reuters reports »

Baking changes to global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

15:27
01/20/20
01/20
15:27
01/20/20
15:27
Periodicals
Alphabet calls for 'proportionate approach' to AI regulation, Reuters reports »

Sundar Pichai, the CEO of…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

, GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

15:24
01/20/20
01/20
15:24
01/20/20
15:24
Periodicals
Alphabet CEO backs temporary ban on facial-recognition, Reuters reports »

The EU's proposal…

GOOG

Alphabet

$1,480.28

28.34 (1.95%)

GOOGL

Alphabet Class A

$1,479.12

29.29 (2.02%)

MSFT

Microsoft

$167.06

0.82 (0.49%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 29

    Jan

  • 03

    Feb

  • 03

    Feb

  • 10

    Feb

  • 25

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

, AER

AerCap

$62.35

-0.18 (-0.29%)

15:10
01/20/20
01/20
15:10
01/20/20
15:10
Periodicals
AerCap CEO warns against panic discounts for Boeing 737 MAX, Reuters says »

Owners of Boeing's…

BA

Boeing

$324.11

-7.89 (-2.38%)

AER

AerCap

$62.35

-0.18 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 13

    Feb

BA

Boeing

$324.11

-7.89 (-2.38%)

15:05
01/20/20
01/20
15:05
01/20/20
15:05
Periodicals
Aviation executive says Boeing should ditch 'MAX,' NY Post reports »

Steven Udvar-Hazy is the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

BA

Boeing

$324.11

-7.89 (-2.38%)

14:08
01/20/20
01/20
14:08
01/20/20
14:08
Periodicals
Boeing close to securing $10B loan, Bloomberg reports »

Boeing is close to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

CAE

CAE

$29.65

-0.14 (-0.47%)

14:05
01/20/20
01/20
14:05
01/20/20
14:05
Hot Stocks
CAE appoints Todd Probert as Group President, Defense & Security »

CAE announced the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

ACC

American Campus

$46.31

-0.085 (-0.18%)

14:03
01/20/20
01/20
14:03
01/20/20
14:03
Recommendations
American Campus analyst commentary  »

American Campus announces…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Feb

UPS

UPS

$118.61

0.005 (0.00%)

14:02
01/20/20
01/20
14:02
01/20/20
14:02
Hot Stocks
UPS launches e-commerce plug-ins as part of UPS Digital Access Program »

UPS announced that it is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

WINS

Wins Finance

$12.50

-1.2 (-8.76%)

13:58
01/20/20
01/20
13:58
01/20/20
13:58
Hot Stocks
Wins Finance announces submission of compliance plan to Nasdaq »

Wins Finance announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MSFT

Microsoft

$167.06

0.82 (0.49%)

13:55
01/20/20
01/20
13:55
01/20/20
13:55
Recommendations
Microsoft price target raised to $175 from $160 at Stifel »

Stifel analyst Brad…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Jan

  • 25

    Feb

SFTBY

SoftBank

$0.00

(0.00%)

, SFTBF

SoftBank

$0.00

(0.00%)

13:52
01/20/20
01/20
13:52
01/20/20
13:52
Periodicals
Softbank says WeWork still good business at core, Bloomberg reports »

SoftBank (SFTBY;SFTBF)…

SFTBY

SoftBank

$0.00

(0.00%)

SFTBF

SoftBank

$0.00

(0.00%)

WE

We Company

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Feb

EGLE

Eagle Bulk Shipping

$4.25

-0.03 (-0.70%)

13:40
01/20/20
01/20
13:40
01/20/20
13:40
Conference/Events
Eagle Bulk Shipping to host conference call »

Management discusses…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:39
01/20/20
01/20
13:39
01/20/20
13:39
Downgrade
Siam Commercial Bank rating change at JPMorgan »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:38
01/20/20
01/20
13:38
01/20/20
13:38
Downgrade
Siam Commercial Bank rating change at Credit Suisse »

Siam Commercial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:37
01/20/20
01/20
13:37
01/20/20
13:37
Downgrade
Siam Commercial Bank rating change at Macquarie »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMUUY

Siam Commercial Bank

$0.00

(0.00%)

13:37
01/20/20
01/20
13:37
01/20/20
13:37
Downgrade
Siam Commercial Bank rating change at Citi »

Siam Commercial Bank…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CNVVY

ConvaTec

$0.00

(0.00%)

13:35
01/20/20
01/20
13:35
01/20/20
13:35
Downgrade
ConvaTec rating change at JPMorgan »

ConvaTec downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.